IDH2-mutated near ETP-ALL with aggressive leukemia cutis and brisk response to venetoclax and decitabine
Poorva Vaidya(University of California San Diego), James K. Mangan(UC San Diego Health System), Brian Hinds(University of California San Diego), Michelle Don(University of California San Diego), Huan‐You Wang(University of California San Diego)
Cited by 3
Related Papers
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2019|274
Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
|BMC Cancer|2016|194
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|192
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
|Journal of the National Comprehensive Cancer Network|2022|126
Extracavitary KSHV-associated Large B-Cell Lymphoma
|The American Journal of Surgical Pathology|2012|110